Patents Examined by Anoop K. Singh
  • Patent number: 11401316
    Abstract: The present invention pertains to novel high avidity antigen recognizing constructs against Human Papilloma Virus antigens. The invention provides novel T cell receptor (TCR) based molecules which are selective and specific for HPV 16/18 proteins E5, E6 and E7. The TCR of the invention, and HPV antigen-binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of HPV infection, as well as for the diagnosis, treatment and prevention of HPV infection mediated secondary diseases as HPV infection caused cancers, such as cervical, nasopharyngeal or head and neck cancer. Further provided are nucleic acids encoding the proteins of the invention, and recombinant cells expressing the same.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 2, 2022
    Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT
    Inventors: Thomas Blankenstein, Gerald Willimsky
  • Patent number: 11390851
    Abstract: The present invention provides a method for generation, isolation, detection and/or analysis of cardiomyocytes derived from a starting cell composition comprising pluripotent and/or multipotent stem cells, the method comprising the steps a) differentiating said pluripotent and/or multipotent stem cells into cardiovascular cells, thereby generating a sample comprising cardiomyocytes and non-cardiomyocytes; and b) labeling the non-cardiomyocytes of said sample with more than one antibody or antigen binding fragment thereof specific for antigens of non-cardiomyocytes and c) depleting said labeled non-cardiomyocytes from said sample; and optionally d) labeling the cardiomyocytes of said sample with at least one antibody or antigen binding fragment thereof specific for antigen(s) of cardiomyocytes; and e) enriching said labeled cardiomyocytes and detecting and isolating cardiomyocyte subtypes derived from said pluripotent and/or multipotent stem cells.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: July 19, 2022
    Assignee: Miltenyi Biotec B.V. & Co. KG
    Inventors: Kristin Becker, Dominik Eckardt, Andreas Bosio
  • Patent number: 11377639
    Abstract: Animal cells, notably adult fibroblasts, are advantageously reprogrammed in direct lineage reprogramming methods using defined factors to produce proliferative and multipotent induced cardiac progenitor cells (iCPC). The iCPC thus produced can be differentiated under suitable differentiation conditions to cardiac lineage cells including cardiomyocytes, smooth muscle cells, and endothelial cells, as evidenced by expression of lineage specific markers. Sets of factors effective in combination to reprogram the fibroblasts can include a set that includes some or all of 5 factors (Mesp1, Baf60c, Nkx2.5, Gata4, Tbx5), a set that includes some or all of 11 factors (Mesp1, Mesp2, Gata4, Gata6, Baf60c, SRF, Isl1, Nkx2.5, Irx4, Tbx5, Tbx20), a set that includes some or all of 18 factors (T, Mesp1, Mesp2, Tbx5, Tbx20, Isl1, Gata4, Gata6, Irx4, Nkx2.5, Hand1, Hand2, Tbx20, Tbx18, Tip60, Baf60c, SRF, Hey2), and a set that includes some or all of 22 factors (T, Mesp1, Mesp2, Tbx5, Tbx20, Isl1, Gata4, Gata6, Irx4, Nkx2.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: July 5, 2022
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Timothy Joseph Kamp, Pratik Arvind Lalit
  • Patent number: 11364308
    Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AA V virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: June 21, 2022
    Assignee: 4D Molecular Therapeutics Inc.
    Inventors: David H. Kirn, Melissa Kotterman, David Schaffer
  • Patent number: 11359180
    Abstract: Provided is a method for producing myocardial cells from pluripotent stem cells. The myocardial cell production method provided by the present invention includes supplying an artificially produced synthetic peptide to a cell culture that contains pluripotent stem cells. The synthetic peptide is a peptide that contains a myocardial cell differentiation-inducing peptide sequence that induces pluripotent stem cells into myocardial cells. The myocardial cell differentiation-inducing peptide sequence is an amino acid sequence selected from the group consisting of (i) an amino acid sequence constituting the signal peptide of any protein belonging to the amyloid precursor protein (APP) family, (ii) a partial amino acid sequence of the amino acid sequence according to (i), and (iii) a modified amino acid sequence from the amino acid sequence according to (i) or (ii).
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: June 14, 2022
    Assignees: Toagosei Co., Ltd., Kyoto University
    Inventors: Tetsuhiko Yoshida, Kenichi Tanaka, Nahoko Baileykobayashi, Yoshinori Yoshida
  • Patent number: 11345734
    Abstract: The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) and a signal transduction modifying protein, selected from one of the following: (i) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), but lacks a kinase domain; (ii) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a phosphatase domain; (iii) a fusion protein which comprises (a) an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) or from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM); and (ii) a heterologous domain.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: May 31, 2022
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba, Simon Thomas, Khai Kong
  • Patent number: 11326185
    Abstract: The present invention relates to stable and high-producing site-specific integration (SSI) host cells, e. g. Chinese hamster ovary (CHO)-derived host cells, methods to produce and to use them.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 10, 2022
    Assignees: LONZA BIOLOGICS PLC, PFIZER INC.
    Inventors: James Rance, Robert Young, Michael J. Agostino, Mark Moffat, Lin Zhang, Baohong Zhang
  • Patent number: 11324778
    Abstract: Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O2 tension, including manipulation of Ca2+ under high O2 tension and contacting oocytes with serine threonine kinase inhibitors under low O2 tension, isolating inner cell masses (ICMs) from the activated oocytes, and culturing the cells of the isolated ICMs under high O2 tension. Moreover, methods are described for the production of stems cells from activated oocytes in the absence of non-human animal products, including the use of human feeder cells/products for culturing ICM/stem cells. Stem cells produced by the disclosed methods are also described.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: May 10, 2022
    Assignee: International Stem Cell Corporation
    Inventors: Elena S. Revazova, Marina V. Pryzhkova, Leonid N. Kuzmichev, Jeffrey D. Janus
  • Patent number: 11319354
    Abstract: Provided is a polynucleotide, including a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein, wherein the cis-regulatory element includes an uncoupling protein 1 enhancer and an uncoupling protein 1 promoter. Also provided is a viral vector including said polynucleotide. Also provided is a method of transfecting a cell or a subject with said polynucleotide or said viral vector.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: May 3, 2022
    Assignee: MASONIC MEDICAL RESEARCH LABORATORY
    Inventor: Zhiqiang Lin
  • Patent number: 11319557
    Abstract: Nucleic acid constructs and methods for rendering modifications to a genome are provided, wherein the modifications comprise null alleles, conditional alleles and null alleles comprising COINs. Multifunctional alleles (MFA) are provided, as well as methods for making them, which afford the ability in a single targeting to introduce an allele that can be used to generate a null allele, a conditional allele, or an allele that is a null allele and that further includes a COIN. MFAs comprise pairs of cognate recombinase recognition sites, an actuating sequence and/or a drug selection cassette, and a nucleotide sequence of interest, and a COIN, wherein upon action of a recombinase a conditional allele with a COIN is formed. In a further embodiment, action of a second recombinase forms an allele that contains only a COIN in sense orientation. In a further embodiment, action by a third recombinase forms an allele that contains only the actuating sequence in sense orientation.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: May 3, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Aris N. Economides, Andrew J. Murphy, Peter Matthew Lengyel, Peter H. A. Yang
  • Patent number: 11306341
    Abstract: Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/L or at a greater concentration than 1.8 g/L more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: April 19, 2022
    Assignee: Genzyme Corporation
    Inventors: Christopher Hwang, Timothy Johnson, Jason Walther, Cheng Cheng, Jonathan Wang, Neha Shah, Seul-A Bae
  • Patent number: 11279954
    Abstract: Provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding TH is linked to the nucleotide sequence encoding CH1 such that they encode a fusion protein TH-CH1. Also provided is a construct comprising (i) a nucleotide sequence which encodes tyrosine hydroxylase (TH), (ii) a nucleotide sequence which encodes GTP-cyclohydrolase I (CH1) and (iii) a nucleotide sequence which encodes Aromatic Amino Acid Dopa Decarboxylase (AADC) wherein the nucleotide sequence encoding AADC is linked to the nucleotide sequence encoding TH such that they encode a fusion protein AADC-TH or TH-AADC. Further provided is a viral vector comprising such nucleotide sequences and its use in the treatment and/or prevention of Parkinson's disease.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: March 22, 2022
    Assignee: Oxford BioMedica (UK) Ltd.
    Inventors: Kyriacos A. Mitrophanous, Scott Ralph, Hannah Stewart, Alan John Kingsman
  • Patent number: 11279949
    Abstract: This disclosure provides modified recombinant retroviruses comprisings containing a 2A-peptide or peptide-like coding sequence operably linked to a heterologous polynucleotide. The disclosure further relates to cells and vector expressing or comprising such vectors and methods of using such modified vectors in the treatment of disease and disorders.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: March 22, 2022
    Assignee: DENOVO BIOPHARMA LLC
    Inventors: Douglas J. Jolly, Amy H. Lin, Andrew Hofacre, Daniel J. Hogan, Derek G. Ostertag
  • Patent number: 11278572
    Abstract: Provided herein are methods of enhancing engraftment of hematopoietic stem cells (HSC) in recipient subjects by reducing expression (or activity) of CXC chemokine receptor 4 (CXCR4). Such methods can be used in gene therapy protocols and in HSC transplantation, for example allowing this to occur without radiation or chemotherapy conditioning as is typically done in non-myeloablative HSC transplant. In some examples, gene editing methods are used to delete one copy of the CXCR4 gene before HSC or bone marrow transplantation, enhancing the efficiency and durability of donor cell repopulation.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: March 22, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jiliang Gao, Philip M. Murphy, David H. McDermott, Marie Siwicki, Harry L. Malech, Joy Liu, Paejonette Jacobs
  • Patent number: 11268107
    Abstract: Described herein are vectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing Smad7. The disclosed AAV vectors and rAAV can be used for therapeutic applications in the treatment and amelioration of muscle wasting, cardiac and/or skeletal muscle wasting associated with cancer cachexia.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: March 8, 2022
    Assignees: Washington State University, Baker Heart and Diabetes Institute
    Inventors: Buel Dantese Rodgers, Paul Gregorevic
  • Patent number: 11268158
    Abstract: The invention is directed to methods of assessing the safety of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing. In particular, the invention provides a method, wherein the oncogenic potential of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing, is determined by determining the percentage of differentiation blocked hematopoietic progenitor cells.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: March 8, 2022
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Brian P. Sorrentino, Sheng Zhou
  • Patent number: 11266129
    Abstract: A transgenic mouse comprising T30A, S32P, Q33L, N39D, and M470Q mutations in GPIIIa, as well as methods for making the transgenic mouse and methods for using the transgenic mouse to screen test compounds are described.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: March 8, 2022
    Inventors: Peter J. Newman, Huiying Zhi
  • Patent number: 11261426
    Abstract: Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: March 1, 2022
    Inventors: Mari Dezawa, Yoshinori Fujiyoshi, Youichi Nabeshima
  • Patent number: 11242508
    Abstract: The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: February 8, 2022
    Assignee: VCELL THERAPEUTICS, INC.
    Inventors: Charles A. Vacanti, Koji Kojima
  • Patent number: 11236402
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 1, 2022
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne